Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab ...

(PR-inside.com) LUND, SE / ACCESS Newswire / September 30, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development. The preclinical data were generated in a research study at Fred Hutch Cancer Center. The results show that the two approaches act on non-overlapping parts of PDAC biology, that the combination reshapes the tumor microenvironment, and reduces tumor burden. The findings emphasize the scientific rationale for Cantargia's planned Phase 1b/2a study of nadunolimab ..

https://reports.pr-inside.com/cantargia ... 228801.htm
Copyright PR-Inside.com 2026